Forfeiture of US Generic Exclusivity: Who's to Blame?
This article was originally published in SRA
Executive Summary
Kurt Karst examines whether the US Food and Drug Administration’s failure to meet the 30-month deadline for approving generics will result in the forfeiture of 180-day exclusivity for first applicants and potentially lead to litigation.